Full history for every metric is available with a Kvantra account
DNA Chip Research Inc. (2397.T)
Key financial summary
Financials in JPY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 361 | 325 | 428 | 328 | 490 | 1,091 | 1,091 |
| Operating profit | ¥m | 40 | 41 | |||||
| Net profit | ¥m | -128 | -172 | -134 | -362 | -248 | -58 | -58 |
| EPS reported | ¥ | -8.61 | -8.58 | |||||
| Operating cashflow per share | ¥ | 12.43 | 12.43 | |||||
| Capex per share | ¥ | 7.00 | 7.00 | |||||
| FCF per share | ¥ | 5.43 | 5.43 | |||||
| Free cash flow | ¥m | 37 | 0 | |||||
| Net debt | ¥m | -411 | -411 | |||||
| Book value equity | ¥m | 674 | 674 | |||||
| Book value per share | ¥ | 99.69 | 99.71 | |||||
| Number of shares | m | 6.76 | 6.76 | |||||
| DPS (TTM paid) | ¥ | 0.00 | 0.00 |
Financial summary
Financials in JPY| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 11.02 | 10.95 | |||||
| P/S LTM | x | 6.81 | 6.77 | |||||
| P/FCF LTM | x | 202.39 | 201.06 | |||||
| EV/EBITDA LTM | x | 3,139.75 | 3,925.57 | |||||
| EV/Sales LTM | x | 6.43 | 6.39 | |||||
| Earnings Yield LTM | % | -0.78% | -0.79% | |||||
| FCF Yield | % | 0.49% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -8.63% | -8.27% | |||||
| ROIC | % | 5.50% | 5.50% | |||||
| Operating margin | % | 3.64% | 3.64% | |||||
| Gross margin | % | 52.27% | 52.27% | |||||
| FCF/Sales | % | 3.36% | 3.36% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +122.49% | +122.49% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -183.64 | -183.64 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -5.53% | -5.56% | |||||
| Net debt/Equity | x | -0.61 | -0.61 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Headquartered in Tokyo, Japan, DNA Chip Research Inc. specializes in the creation of DNA microarrays. Its operations encompass research and development, bespoke contract research, and comprehensive diagnostic assistance. A notable product is the Tbone EX Kit, supplied to forensic laboratories across Japan, including those within law enforcement agencies and academic institutions. Furthermore, the company is behind the development of the EGFR (epidermal growth factor receptor) Liquid gene analysis software, a diagnostic tool designed to identify mutations in the EGFR-encoding gene from DNA harvested from plasma or cancerous tissues. This software also assesses the effectiveness of EGFR tyrosine kinase inhibitors for individuals suffering from non-small cell lung cancer. Beyond this, they are actively engaged in creating a comprehensive gene panel for cancer screening through advanced sequencing technologies. Established in 1999, the firm operates out of Tokyo, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
DNA Chip Research Inc. (2397.T)
Headquartered in Tokyo, Japan, DNA Chip Research Inc. specializes in the creation of DNA microarrays. Its operations encompass research and development, bespoke contract research, and comprehensive diagnostic assistance. A notable product is the Tbone EX Kit, supplied to forensic laboratories across Japan, including those within law enforcement agencies and academic institutions. Furthermore, the company is behind the development of the EGFR (epidermal growth factor receptor) Liquid gene analysis software, a diagnostic tool designed to identify mutations in the EGFR-encoding gene from DNA harvested from plasma or cancerous tissues. This software also assesses the effectiveness of EGFR tyrosine kinase inhibitors for individuals suffering from non-small cell lung cancer. Beyond this, they are actively engaged in creating a comprehensive gene panel for cancer screening through advanced sequencing technologies. Established in 1999, the firm operates out of Tokyo, Japan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free